GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmala Biotech Holdings Inc (OTCPK:MDXXF) » Definitions » Total Stockholders Equity

MDXXF (Pharmala Biotech Holdings) Total Stockholders Equity : $1.36 Mil (As of Nov. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Pharmala Biotech Holdings Total Stockholders Equity?

Pharmala Biotech Holdings's Total Stockholders Equity for the quarter that ended in Nov. 2024 was $1.36 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Pharmala Biotech Holdings's Book Value per Share for the quarter that ended in Nov. 2024 was $0.01. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Pharmala Biotech Holdings's Debt-to-Equity for the quarter that ended in Nov. 2024 was 0.00.

Pharmala Biotech Holdings Total Stockholders Equity Historical Data

The historical data trend for Pharmala Biotech Holdings's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmala Biotech Holdings Total Stockholders Equity Chart

Pharmala Biotech Holdings Annual Data
Trend Aug21 Aug22 Aug23 Aug24
Total Stockholders Equity
2.11 1.48 1.03 1.45

Pharmala Biotech Holdings Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 Aug24 Nov24
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.03 1.10 1.00 1.45 1.36

Pharmala Biotech Holdings  (OTCPK:MDXXF) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Pharmala Biotech Holdings's Book Value per Share for the quarter that ended in Nov. 2024 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(1.363-0)/94.290
=0.01

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Pharmala Biotech Holdings's Debt-to-Equity for the quarter that ended in Nov. 2024 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 1.363
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmala Biotech Holdings Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Pharmala Biotech Holdings's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmala Biotech Holdings Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmala Biotech Holdings Inc (OTCPK:MDXXF) » Definitions » Total Stockholders Equity
Comparable Companies
XCNQ:PHRM XCNQ:TELI TSX:BCT TSXV:SBM XCNQ:PREV XCNQ:DOSE TSXV:HEM TSXV:KNE TSXV:RKV XCNQ:BIOV VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
MDMA:Canada
Address
1 Adelaide Street East, Suite 801, Toranto, ON, CAN, M5C 2V9
Website
https://www.pharmala.ca
Pharmala Biotech Holdings Inc is focused on manufacturing and sales of MDMA and MDXX Active Pharmaceutical Ingredients (API) for use in clinical research. Its drug API is manufactured and encapsulated under GMP conditions. The company generates revenue from the sale of tablets and raw MDMA and MDXX compounds/formulations and royalties from licensing of its IP.